Cetrorelix News and Research

RSS
Researchers identify a single protein as root cause of multiple allergic reactions

Researchers identify a single protein as root cause of multiple allergic reactions

Aeterna enters into agreements to transfer manufacturing license for Cetrotide to Merck KGaA

Aeterna enters into agreements to transfer manufacturing license for Cetrotide to Merck KGaA

Merck Serono announces recipients of second Grant for Fertility Innovation

Merck Serono announces recipients of second Grant for Fertility Innovation

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

MicroStockProfit.com releases investment report on AEterna Zentaris

MicroStockProfit.com releases investment report on AEterna Zentaris

BeaconEquity.com announces investment report on AEterna Zentaris

BeaconEquity.com announces investment report on AEterna Zentaris

Æterna Zentaris announces 2009 financial and operating results

Æterna Zentaris announces 2009 financial and operating results

Spectrum Pharmaceuticals discontinues the development of ozarelix in BPH

Spectrum Pharmaceuticals discontinues the development of ozarelix in BPH

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial

Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

AEterna Zentari completes recruitment for phase 3 trial with Cetrorelix in benign prostatic hyperplasia

AEterna Zentari completes recruitment for phase 3 trial with Cetrorelix in benign prostatic hyperplasia

Promising new therapy for protecting the fertility of women with cancer

Promising new therapy for protecting the fertility of women with cancer

Cetrorelix progresses to full development for the treatment of Endometriosis in women

Cetrorelix progresses to full development for the treatment of Endometriosis in women